Overview

• Stereotaxis Q3 2025 revenue declines to $7.5 mln, system revenue significantly lower

• Company reports Q3 net loss of $6.5 mln, slightly wider than last year

• Stereotaxis expects Q4 revenue to exceed $9 mln, driven by new product launches

Outlook

• Stereotaxis expects Q4 revenue to exceed $9 mln, with system revenue around $3 mln

• Company anticipates annual revenue growth of over 20% for 2025

• Stereotaxis projects quarterly revenue to surpass $10 mln in 2026

Result Drivers

• NEW PRODUCT LAUNCHES - MAGiC Sweep and MAGiC ablation catheter contributed to recurring revenue growth

• REGULATORY ADVANCEMENTS - FDA clearance for GenesisX and CE Mark for Synchrony expected to drive future growth

• CATALOG EXPANSION - Ongoing development of catheter innovations to boost commercial results

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Stereotaxis Inc is $4.00, about 30.1% above its November 10 closing price of $2.80

Press Release: ID:nGNXbzKVfj

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)